Skip to main content
. Author manuscript; available in PMC: 2009 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2008 Apr 20;114(3):423–431. doi: 10.1007/s10549-008-0024-3

Figure 2. RFA combined with IL-7 and IL-15 protected animals against tumor recurrence.

Figure 2

FVBN202 transgenic mice (A; 10 mice per group) or Balb/c mice (B; 4 mice per group) were inoculated with neu overexpressing MMC or 4T1 mammary tumors, respectively. Two weeks after the tumor challenge, tumors were either treated with RFA alone or RFA followed by intralesional injection of recombinant IL-7 and IL-15. Control groups remained untreated following tumor challenge. A group of FVBN202 transgenic mice was also inoculated with MMC followed by intralesional injection of IL-7 and IL-15 alone, without prior RFA.